MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BRCA-Mutant Cancer Research

Executive Summary: MK-4827 (Niraparib) is a potent and selective inhibitor of PARP-1 and PARP-2, with IC50 values of 3.8 nM and 2.1 nM, respectively, enabling precise inhibition of DNA repair pathways in cancer cells (APExBIO). It exhibits strong antiproliferative effects (CC50: 10–100 nM) in BRCA-1 and BRCA-2 mutant cancer lines but spares normal cells at micromolar concentrations. In vivo, MK-4827 demonstrates significant tumor suppression in BRCA-1 mutant xenograft models and enhances the therapeutic impact of radiotherapy with low toxicity (Mei et al., 2025). The compound is insoluble in water but highly soluble in DMSO (≥32 mg/mL) and ethanol (≥50.9 mg/mL, gentle warming), supporting diverse experimental workflows. This article contextualizes MK-4827 within the landscape of DNA damage response inhibitors, clarifying its mechanism, application boundaries, and integration into translational oncology research.

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are enzymes that catalyze poly(ADP-ribosyl)ation of target proteins, primarily using β-NAD+ as a substrate. PARP-1 and PARP-2 are critical for the repair of DNA single-strand breaks (SSBs) through the base excision repair (BER) pathway (Mei et al., 2025). Inhibition of PARP activity leads to the persistence of SSBs, which can convert into double-strand breaks (DSBs) during DNA replication. The homologous recombination (HR) pathway, dependent on BRCA-1 and BRCA-2 proteins, is required for accurate DSB repair. Cells deficient in BRCA-1 or BRCA-2 cannot efficiently resolve DSBs, resulting in genomic instability and cell death—a mechanism termed synthetic lethality (PCI32765.com). Consequently, selective PARP inhibitors like MK-4827 are highly effective in treating cancers with HR deficiencies, such as BRCA-mutant breast, ovarian, and prostate cancers.

Mechanism of Action of MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor

MK-4827 (Niraparib) is a small molecule inhibitor (MW: 320.39; C19H20N4O) that competitively binds to the NAD+ site of PARP-1 and PARP-2 enzymes (APExBIO). Inhibition is observed at IC50 values of 3.8 nM (PARP-1) and 2.1 nM (PARP-2), demonstrating high selectivity. By blocking the catalytic activity of PARPs, MK-4827 prevents poly(ADP-ribosyl)ation of DNA repair proteins, resulting in accumulation of unrepaired SSBs. During DNA replication, these lesions escalate to DSBs, especially lethal for cells lacking functional BRCA-1 or BRCA-2 due to their inability to perform HR-mediated repair (Mei et al., 2025). MK-4827 thus exploits synthetic lethality, selectively eliminating HR-deficient tumor cells while sparing normal cells. Additionally, the compound enhances radiosensitivity and synergizes with chemotherapeutic agents, further impairing tumor cell viability.

Evidence & Benchmarks

• MK-4827 (Niraparib) inhibits PARP-1 (IC50: 3.8 nM) and PARP-2 (IC50: 2.1 nM) enzymatic activity in biochemical assays (APExBIO).
• BRCA-1 and BRCA-2 mutant tumor cell lines show potent antiproliferative response to MK-4827, with CC50 values between 10–100 nM, while normal epithelial cells (prostate, mammary) tolerate micromolar concentrations (DoripenemHydrate.com).
• In vivo, MK-4827 suppresses tumor growth in BRCA-1 mutant MDA-MB-436 xenografts and enhances radiotherapy efficacy with minimal toxicity in mouse models (Mei et al., 2025).
• Combination of hyperthermia-induced BRCA2 reduction with MK-4827 increases tumor suppression and prolongs survival in BRCA2-proficient ovarian carcinoma mouse models (Mei et al., 2025).
• MK-4827 is soluble at ≥32 mg/mL in DMSO and ≥50.9 mg/mL in ethanol (gentle warming), but insoluble in water, guiding formulation and assay development (APExBIO).
• MK-4827 is widely referenced as a cornerstone tool for translational cancer research targeting DNA damage response and PARP signaling pathways (Strategic Horizons in PARP Inhibition).

This article extends the scope of prior coverage by providing updated evidence on hyperthermia–PARP inhibitor synergy and clarifying selectivity parameters for MK-4827. For a broader context on radio- and chemo-potentiation, see PCI32765.com, which focuses on broader PARP inhibitor resistance mechanisms, whereas this article details MK-4827's specific pharmacology.

Applications, Limits & Misconceptions

Applications: MK-4827 (Niraparib) is used in:

• BRCA-1/-2 mutant cancer cell proliferation assays and xenograft models.
• DNA damage response and repair pathway inhibition studies, including synthetic lethality experiments.
• Radiosensitization and combination therapy research targeting DNA repair-deficient tumors.
• Preclinical development of PARP inhibitor-based strategies in breast, ovarian, lung, and prostate cancers.

Limits: Efficacy is reduced in BRCA-proficient tumors unless combined with agents (e.g., hyperthermia) that induce HR deficiency (Mei et al., 2025). Long-term storage of MK-4827 in solution is not recommended due to compound stability concerns (APExBIO).

Common Pitfalls or Misconceptions

• MK-4827 is not effective in BRCA-proficient or HR-competent tumors unless HR is experimentally compromised.
• It does not directly induce DNA damage; efficacy relies on endogenous DNA repair deficiencies.
• Solubility in water is negligible; use DMSO or ethanol for stock solutions and experimental formulations.
• Cellular resistance can develop via restoration of HR or drug efflux mechanisms.
• MK-4827 is a research-use-only compound and not approved for direct clinical therapy.

Workflow Integration & Parameters

MK-4827 (Niraparib) is supplied by APExBIO as a powder (SKU: A3617). For in vitro assays, prepare stock solutions at ≥32 mg/mL in DMSO or ≥50.9 mg/mL in ethanol with gentle warming. Avoid prolonged storage of solutions; aliquot and store at -20°C (product page). Working concentrations typically range from 10 nM to 10 µM, depending on cell line sensitivity and application. In vivo dosing regimens should be empirically established based on animal model and tumor type. Monitor for potential resistance mechanisms, such as HR restoration, during long-term exposure. For detailed workflow guidance, see this strategic insight, which elaborates on translational protocols and combinatorial strategies; this article provides updated pharmacological benchmarks and stability data for MK-4827.

Conclusion & Outlook

MK-4827 (Niraparib) is a validated, selective PARP-1/-2 inhibitor with robust potency for BRCA-mutant and homologous recombination-deficient cancer research. Its strong selectivity, oral bioavailability, and compatibility with combination strategies make it integral to DNA repair pathway studies and preclinical drug development. Ongoing research focuses on overcoming resistance in BRCA-proficient tumors, with combination modalities such as hyperthermia emerging as promising adjuncts (Mei et al., 2025). As a reference compound from APExBIO, MK-4827 will continue to underpin advances in synthetic lethality, radiosensitization, and next-generation anti-cancer strategies.